Raloxifene
Raloxifene Brand names, Raloxifene Analogs
Raloxifene Brand Names Mixture
- No information avaliable
Raloxifene Chemical_Formula
C28H27NO4S
Raloxifene RX_link
http://www.rxlist.com/cgi/generic/raloxif.htm
Raloxifene fda sheet
Raloxifene msds (material safety sheet)
Raloxifene Synthesis Reference
C. D. Jones et al., J. Med. Cem. 27, 1057(1984)
Raloxifene Molecular Weight
473.584 g/mol
Raloxifene Melting Point
143-147oC
Raloxifene H2O Solubility
0.25mg/L
Raloxifene State
Solid
Raloxifene LogP
5.749
Raloxifene Dosage Forms
Tablet
Raloxifene Indication
For the prevention of osteoporosis in post-menopausal women
Raloxifene Pharmacology
Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer.
Raloxifene Absorption
Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%
Raloxifene side effects and Toxicity
No information avaliable
Raloxifene Patient Information
PATIENT INFORMATION
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
Raloxifene Organisms Affected
Humans and other mammals
